He B, Gampe Jr RT, Kole AJ, Hnat AT, Stanley TB, An G et al.. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16: 425-438

Laboratories for Reproductive Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Molecular Cell (Impact Factor: 14.02). 12/2004; 16(3):425-38. DOI: 10.1016/j.molcel.2004.09.036
Source: PubMed


The androgen receptor (AR) is required for male sex development and contributes to prostate cancer cell survival. In contrast to other nuclear receptors that bind the LXXLL motifs of coactivators, the AR ligand binding domain is preferentially engaged in an interdomain interaction with the AR FXXLF motif. Reported here are crystal structures of the ligand-activated AR ligand binding domain with and without bound FXXLF and LXXLL peptides. Key residues that establish motif binding specificity are identified through comparative structure-function and mutagenesis studies. A mechanism in prostate cancer is suggested by a functional AR mutation at a specificity-determining residue that recovers coactivator LXXLL motif binding. An activation function transition hypothesis is proposed in which an evolutionary decline in LXXLL motif binding parallels expansion and functional dominance of the NH(2)-terminal transactivation domain in the steroid receptor subfamily.

Download full-text


Available from: Robert T Gampe, Aug 19, 2014
  • Source
    • "rcsb.org/pdb/) He et al. (2004). The Surflex-Dock program interfaced with SYBYL 7.3 was adopted to dock the compounds to the ligand binding domain (LBD) of human AR. "
    [Show abstract] [Hide abstract]
    ABSTRACT: While some synthetic chemicals have been demonstrated to disrupt normal endocrine function by binding to the androgen receptor (AR), the mechanism by which ligands bind to the ligand binding domain (LBD) remained unclear. In this study, docking and comparative molecular similarity index analysis (CoMSIA) were performed to study the AR ligand binding mechanism of steroids and non-steroidal chemicals. The obtained docking conformations and predictive CoMSIA models (r(pred)(2)values as 0.842 and 0.554) indicated the primary interaction site and key residues in the binding process. The major factors influence the binding affinity of steroids and non-steroidal chemicals were electrostatic and hydrophobic interactions, respectively. The results indicated that besides amino-acid residues Gln711, Arg752 and Thr877 which have previously been reported to be important in binding ligands, Leu701 and Leu704 are also important. Residues Val746, Met749 and Phe764 are crucial only for steroids, while Met742 and Met787 are important only for non-steroidal chemicals. This knowledge of key interactions and important amino-acid residues governing ligands to the AR allow better prediction of potency of AR agonists so that their potential to disrupt AR-mediated pathways and to design less potent alternatives.
    Ecotoxicology and Environmental Safety 12/2012; 89. DOI:10.1016/j.ecoenv.2012.11.020 · 2.76 Impact Factor
  • Source
    • "ligand binding, the AR undergoes several conformational changes including the interdomain interaction between the 23FQNLF27 motif near the amino terminus and the activation function-2 (AF2) domain near the ligand-bound carboxyl terminus (N/C interaction) [42] [43]. This N/C interaction is critical for toxicity through stabilizing the AR and enhancing hormone binding [44] [45]. Selective androgen receptor modulators such as RTI-016 and RTI- 051b prevent the N/C interaction and ameliorated AR aggregation and toxicity while retaining AR transcriptional function, highlighting a novel therapeutic strategy for SBMA (Figure 1) [45]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Spinal and bulbar muscular atrophy (SBMA) is the first member identified among polyglutamine diseases characterized by slowly progressive muscle weakness and atrophy of the bulbar, facial, and limb muscles pathologically associated with motor neuron loss in the spinal cord and brainstem. Androgen receptor (AR), a disease-causing protein of SBMA, is a well-characterized ligand-activated transcription factor, and androgen binding induces nuclear translocation, conformational change and recruitment of coregulators for transactivation of AR target genes. Some therapeutic strategies for SBMA are based on these native functions of AR. Since ligand-induced nuclear translocation of mutant AR has been shown to be a critical step in motor neuron degeneration in SBMA, androgen deprivation therapies using leuprorelin and dutasteride have been developed and translated into clinical trials. Although the results of these trials are inconclusive, renewed clinical trials with more sophisticated design might prove the effectiveness of hormonal intervention in the near future. Furthermore, based on the normal function of AR, therapies targeted for conformational changes of AR including amino-terminal (N) and carboxy-terminal (C) (N/C) interaction and transcriptional coregulators might be promising. Other treatments targeted for mitochondrial function, ubiquitin-proteasome system (UPS), and autophagy could be applicable for all types of polyglutamine diseases.
    Neural Plasticity 06/2012; 2012(7):369284. DOI:10.1155/2012/369284 · 3.58 Impact Factor
  • Source
    • "Such a favoured response reflects a greater dependence of the AR-Pro723S mutant on FKBP52 for normal activity. Pro723 lies within the signature sequence conserved among all steroid receptors (Brelivet et al., 2004), close to a region directly involved in ligand binding and is situated in a solvent exposed loop between helices 3 and 4, which combine together with the mobile helix 12 to form the AF2 coactivator binding pocket (He et al., 2004; Matias et al., 2000b). For AR, AF2 initially has a preferred interaction with the AR N-terminal domain, resulting in an intramolecular fold that precedes receptor dimerization and appears critical for AR function (He et al., 2001; He et al., 2004; Schaufele et al., 2005). "

    Protein Interactions, 03/2012; , ISBN: 978-953-51-0244-1
Show more